KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Thermo Fisher Scientific (TMO) Restructuring Costs (2016 - 2025)

Thermo Fisher Scientific's Restructuring Costs history spans 17 years, with the latest figure at $46.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Restructuring Costs fell 79.82% year-over-year to $46.0 million, compared with a TTM value of $361.0 million through Dec 2025, down 4.75%, and an annual FY2025 reading of $362.0 million, up 624.0% over the prior year.
  • Restructuring Costs for Q4 2025 was $46.0 million at Thermo Fisher Scientific, down from $135.0 million in the prior quarter.
  • The five-year high for Restructuring Costs was $228.0 million in Q4 2024, with the low at $2.0 million in Q2 2022.
  • Average Restructuring Costs over 5 years is $75.5 million, with a median of $66.0 million recorded in 2022.
  • Year-over-year, Restructuring Costs plummeted 85.71% in 2022 and then surged 5500.0% in 2023.
  • Tracing TMO's Restructuring Costs over 5 years: stood at $46.0 million in 2021, then grew by 19.57% to $55.0 million in 2022, then soared by 45.45% to $80.0 million in 2023, then soared by 185.0% to $228.0 million in 2024, then tumbled by 79.82% to $46.0 million in 2025.
  • Per Business Quant, the three most recent readings for TMO's Restructuring Costs are $46.0 million (Q4 2025), $135.0 million (Q3 2025), and $82.0 million (Q2 2025).